Skip to main content

Table 3 Longitudinal association of biomarkers of neurodegenerative diseases and subjective cognitive complaints with risk of all-cause dementia (ESTHER cohort, nested case–control study)

From: Subjective cognitive complaints and blood biomarkers of neurodegenerative diseases: a longitudinal cohort study

 

Cases (n = 226), N (%)

Controls, (n = 476), N (%)

Model 1a odds ratio (95%CI), p-valuec

Model 2b odds ratio (95%CI), p-valuec

Subjective cognitive complaints

 No

36 (15.9)

115 (24.2)

Reference

Reference

 Occasional

142 (62.8)

303 (63.7)

1.22 (0.75–1.96), 0.4220

1.26 (0.76–2.08), 0.3748

 Persistent

48 (21.2)

58 (12.2)

1.70 (0.93–3.12), 0.0874

1.58 (0.82–3.05), 0.1684

GFAP

 GFAPQ1–3

117 (51.8)

403 (84.7)

Reference

Reference

 GFAPQ4

109 (48.2)

70 (14.7)

2.93 (1.94–4.41), < 0.0001

3.17 (2.03–4.95), < 0.0001

Subjective cognitive complaints and GFAP

 No and GFAPQ1–3

22 (9.7)

104 (21.8)

Reference

Reference

 No and GFAPQ4

14 (6.2)

10 (2.1)

4.06 (1.41–11.68), 0.0093

3.98 (1.27–12.48), 0.0180

 Occasional and GFAPQ1–3

76 (33.6)

251 (52.7)

1.30 (0.74–2.29), 0.3575

1.31 (0.73–2.38), 0.3674

 Occasional and GFAPQ4

66 (29.2)

51 (10.7)

2.81 (1.47–5.38), 0.0017

3.02 (1.51–6.01), 0.0017

 Persistent and GFAPQ1–3

19 (8.4)

48 (10.1)

1.22 (0.57–2.63), 0.6138

0.99 (0.43–2.30), 0.9809

 Persistent and GFAPQ4

29 (12.8)

9 (1.9)

7.39 (2.89–18.88), < 0.0001

7.52 (2.79–20.29), < 0.0001

NfL

 NfLQ1–3

136 (60.2)

388 (81.5)

Reference

Reference

 NfLQ4

90 (39.8)

85 (17.9)

1.32 (0.87–2.00), 0.1926

1.38 (0.88–2.17), 0.1573

Subjective cognitive complaints and NfL

 No and NfLQ1–3

22 (9.7)

96 (20.2)

Reference

Reference

 No and NfLQ4

14 (6.2)

18 (3.8)

1.35 (0.53–3.41), 0.5273

1.52 (0.57–4.07), 0.4025

 Occasional and NfLQ1–3

83 (36.7)

249 (52.3)

1.18 (0.66–2.10), 0.5737

1.25 (0.68–2.31), 0.4662

 Occasional and NfLQ4

59 (26.1)

53 (11.1)

1.77 (0.91–3.46), 0.0950

1.95 (0.96–3.99), 0.0664

 Persistent and NfLQ1–3

31 (13.7)

43 (9.0)

2.05 (0.99–4.25), 0.0547

2.00 (0.91–4.42), 0.0851

 Persistent and NfLQ4

17 (7.5)

14 (2.9)

1.70 (0.66–4.36), 0.2689

1.63 (0.60–4.44), 0.3385

p-tau181

 p-tau181Q1–3

152 (67.3)

386 (81.1)

Reference

Reference

 p-tau181Q4

74 (32.7)

90 (18.9)

1.20 (0.80–1.82), 0.3809

1.21 (0.78–1.89), 0.3936

Subjective cognitive complaints and p-tau181

 No and p-tau181Q1–3

24 (10.6)

93 (19.5)

Reference

Reference

 No and p-tau181Q4

12 (5.3)

22 (4.6)

1.07 (0.42–2.72), 0.8875

1.00 (0.37–2.69), 0.9959

 Occasional and p-tau181Q1–3

97 (42.9)

248 (52.1)

1.18 (0.67–2.07), 0.5685

1.18 (0.65–2.13), 0.5909

 Occasional and p-tau181Q4

45 (19.9)

55 (11.6)

1.46 (0.74–2.87), 0.2749

1.55 (0.76–3.19), 0.2308

 Persistent and p-tau181Q1–3

31 (13.7)

45 (9.5)

1.63 (0.79–3.34), 0.1854

1.53 (0.71–3.31), 0.2796

 Persistent and p-tau181Q4

17 (7.5)

13 (2.7)

2.07 (0.79–5.43), 0.1413

1.73 (0.62–4.81), 0.2966

  1. Percentages might not sum up to 100 because of rounding and missing values
  2. In this sample GFAPQ4 ≥ 122.00 pg/mL; NfLQ4 ≥ 21.20 pg/mL; p-tau181Q4 ≥ 2.06 pg/mL
  3. CI confidence interval, GFAP glial fibrillary acidic protein, NfL neurofilament light chain, p-tau181 phosphorylated tau181, Q quartile
  4. aLogistic regression model 1 adjusted for age (continuous), sex, and educational level
  5. bLogistic regression model 2 additionally adjusted for lifetime history of stroke, myocardial infarction, diabetes, lifetime history of depression, and APOE ε4 genotype
  6. cp-value derived from the logistic regression models